<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120691</url>
  </required_header>
  <id_info>
    <org_study_id>CQVA149A2304</org_study_id>
    <secondary_id>2009-013256-69</secondary_id>
    <nct_id>NCT01120691</nct_id>
  </id_info>
  <brief_title>Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations</brief_title>
  <acronym>SPARK</acronym>
  <official_title>A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in
      patients with severe to very severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period.</measure>
    <time_frame>64 weeks</time_frame>
    <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and Open-label Tiotropium Treatment Arms During the Treatment Period.</measure>
    <time_frame>76 weeks</time_frame>
    <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Between QVA149, NVA237 and Open Label Tiotropium During the Treatment Period</measure>
    <time_frame>64 weeks</time_frame>
    <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Requiring the Use of Both Systemic Glucocorticosteroids and Antibiotics</measure>
    <time_frame>64 weeks</time_frame>
    <description>Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Moderate or Severe Exacerbation That Required Treatment With Systemic Corticosteroids and Antibiotics</measure>
    <time_frame>64 weeks</time_frame>
    <description>The number of exacerbation days is defined as the sum of the duration of days recorded as an exacerbation for all exacerbations recorded per patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.) During the Treatment Period.</measure>
    <time_frame>64 weeks</time_frame>
    <description>Time to Study Withdrawal or Premature Discontinuation for Any Reason was analyzed for each treatment group using a Kaplan-Meier estimation for the modified safety set. Patients who did not discontinue early were censored at the final visit of the treatment phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.)During the Treatment Period</measure>
    <time_frame>64 weeks</time_frame>
    <description>Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason was analyzed for each treatment group using a Kaplan-Meier estimation for the modified safety set. Patients who did not discontinue early were censored at the final visit of the treatment phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Rates of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations for Multiple COPD Exacerbation at Different Time Points</measure>
    <time_frame>26, 52, 64, 76 weeks</time_frame>
    <description>Cumulative rates were estimated using Anderson and Gill method. Chronic Obstructive Pulmonary Disease (COPD) exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if treatment for moderate severity and hospitalization were required. Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Forced Expiratory Volume in 1 Second (FEV-1) After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium</measure>
    <time_frame>4, 12, 26, 38, 52 and 64 weeks</time_frame>
    <description>Pulmonary function assessments were performed using centralized spirometry. The spirometer was customized and programmed according to the requirements of the study protocol in accordance with American Thoracic Society (ATS) standards.
Spirometry measurements taken were FEV1 at -45 minutes and -15 minutes pre-dose. Three acceptable maneuvers had to be performed for each time point. The FEV1 values recorded had to be the highest values measured irrespective of whether or not they occurred on the same curve.
The mixed model for analysis contained treatment as a fixed effect with average of the 45 minutes and 15 minutes pre dose FEV1 measurements at day 1 as the baseline measurement, FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at -14 Day) as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Forced Vital Capacity (FVC)After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium</measure>
    <time_frame>4, 12, 26, 38, 52 and 64 weeks</time_frame>
    <description>Pulmonary function assessments were performed using centralized spirometry. The spirometer was customized and programmed according to the requirements of the study protocol in accordance with American Thoracic Society (ATS) standards.
Pre-dose Forced Vital Capacity (FVC) is defined as the average of the -15 minutes and the -45 minutes FVC values. Baseline is defined as the average of the -45 minutes and -15 minutes FVC values taken on day 1 prior to first dose. FVC data taken within 6h of rescue medication or within 7 days of systemic corticosteroid is excluded from this analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Daily Use (Number of Puffs) of Rescue Therapy Between QVA149, NVA237 and Open Label Tiotropium From Baseling Over the 64 Week Treatment Period</measure>
    <time_frame>Baseline (14 day run-in), 64 weeks</time_frame>
    <description>The severe or less FEV1 % predicted (post bronchodilator)&gt;=30%; very severe=&gt; FEV1 % predicted(the post bronchodilator)&lt;30%.Number of puffs of rescue medication taken in the previous 12 hours was recorded in patient diary in the morning and in the evening for 26 weeks.The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient.Rescue medication data recorded during the 14 day run-in was used to calculate the baseline.A negative change from baseline indicates improvement. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Percentage of Days Without Rescue Therapy Use Between QVA149,NVA237 and Open Label Tiotropium Over the 64 Week Treatment Period</measure>
    <time_frame>Baseline (14 day run-in), 64 weeks</time_frame>
    <description>A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. The percentage of days is calculated by the number of days with no rescue medicine use/total number of days with evaluable data X 100. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) Scores Between QVA149, NVA237 and Open Label Tiotropium Over 12, 26, 38, 52 and 64 Weeks of Treatment</measure>
    <time_frame>12, 26, 38, 52 and 64 weeks</time_frame>
    <description>St. George's Respiratory Questionnaire (SGRQ) is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life. Mixed model used baseline SGRQ, baseline inhaled corticosteroid (ICS) use, Forced Expiratory Volume in 1 Second (FEV1) prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates. SGRQ total score is the sum of the scores from the three components; symptoms, activity and impacts.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2224</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>QVA149</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVA237</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>open-label tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QVA149</intervention_name>
    <description>QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).</description>
    <arm_group_label>QVA149</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237</intervention_name>
    <description>NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).</description>
    <arm_group_label>NVA237</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).</description>
    <arm_group_label>open-label tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol/albuterol</intervention_name>
    <description>As needed throughout the study</description>
    <arm_group_label>QVA149</arm_group_label>
    <arm_group_label>NVA237</arm_group_label>
    <arm_group_label>open-label tiotropium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          1. Male or female adults aged ≥40 years, who had signed an informed consent form prior to
             initiation of any study-related procedure.

          2. Patients with severe to very severe Chronic Obstructive Pulmonary Disease COPD (Stage
             III or IV) according to the Global Initiative for Chronic Obstructive Lung Disease
             (GOLD) Guidelines 2008.

          3. Current or ex-smokers with a smoking history of at least 10 pack years (Ten pack-years
             were defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20
             years).

          4. Patients with a post-bronchodilator Forced Expiratory Volume in one second ( FEV1)
             &lt;50% of the predicted normal value, and post-bronchodilator FEV1/ Forced Vital
             Capacity (FVC) &lt;0.70 at Visit 2 (day -14). (Post refers to 1 h after sequential
             inhalation of 84 µg (or equivalent dose) of ipratropium bromide and 400 µg of
             salbutamol).

          5. A documented history of at least 1 COPD exacerbation in the previous 12 months that
             required treatment with systemic glucocorticosteroids and/or antibiotics.

        Exclusion Criteria:

          1. Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy
             test).

          2. Women of child-bearing potential

          3. Patients requiring long term oxygen therapy (&gt; 15 h a day) on a daily basis for
             chronic hypoxemia.

          4. Patients who had a COPD exacerbation that required treatment with antibiotics,
             systemic steroids (oral or intravenous) or hospitalization in the 6 weeks prior to
             visit 1 or between visit 1 (Day -21) and Visit 3 (Day 1).

          5. Patients who developed a COPD exacerbation during a period between visit 1 and 3 were
             ineligible but were permitted to be re-screened after a minimum of 6 weeks after the
             resolution of the COPD exacerbation.

          6. Patients who had a respiratory tract infection within 4 weeks prior to visit 1 (Day
             -21)

             • Patients who developed an upper or lower respiratory tract infection during the
             screening period (up to visit 3 (Day 1) were not eligible, but were permitted to be
             re-screened 4 weeks after the resolution of the respiratory tract infection

          7. Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis (unless
             confirmed by chest x-ray to be no longer active), clinically significant
             bronchiectasis, sarcoidosis, interstitial lung disorder or pulmonary hypertension.

          8. Patients with lung lobectomy, or lung volume reduction or lung transplantation.

          9. Patients who, in the judgment of the investigator, have a clinically relevant
             laboratory abnormality or a clinically significant condition such as (but not limited
             to):

               -  Unstable ischemic heart disease, left ventricular failure, history of myocardial
                  infarction, arrhythmia (excluding chronic stable Atrial Fibrillation (AF).
                  Patients with such events not considered clinically significant by the
                  investigator may be considered for inclusion in the study

               -  history of malignancy of any organ system (including lung cancer), treated or
                  untreated, within the past 5 years whether or not there is evidence of local
                  recurrence or metastases, with the exception of localized basal cell carcinoma of
                  the skin

               -  uncontrolled hypo- or hyperthyroidism, hypokalemia or hyper adrenergic state

               -  narrow-angle glaucoma

               -  Symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to
                  severe renal impairment or urinary retention. (Patients with a Transurethral
                  Resection of Prostate (TURP) were excluded from the study. Patients who underwent
                  full re-section of the prostate could be considered for the study, as well as
                  patients who were asymptomatic and stable on pharmacological treatment for the
                  condition).

               -  any condition which might have compromised patient safety or compliance,
                  interfered with evaluation, or precluded completion of the study

         10. Patients with any history of asthma indicated by (but not limited to) a blood
             eosinophil count &gt; 600/mm3 (at visit 2), or onset of symptoms prior to 40 years.
             Patients without asthma were excluded if their eosinophil count was &gt;600/mm3 at visit
             2.

         11. Patients with allergic rhinitis who used H1 antagonists or intranasal corticosteroids
             intermittently (treatment with a constant dose was permitted).

         12. Patients with eczema (atopic), known high immunoglobulin E (IgE) levels or a known
             positive skin prick test in the last 5 years.

         13. Patients with known history and diagnosis of alpha-1 antitrypsin deficiency.

         14. Patients who were participating in the active phase of a supervised pulmonary
             rehabilitation program.

         15. Patients with Type I or uncontrolled Type II diabetes.

         16. Patients contraindicated for treatment with, or having a history of reactions/
             hypersensitivity to any of the following inhaled drugs or drugs of a similar class or
             any component thereof:

               -  anticholinergic agents

               -  long and short acting beta-2 agonists

               -  sympathomimetic amines.

         17. Patients with a history of long QT syndrome or whose corrected QT interval (QTc)
             measured at visit 2 (Day -14) (Fridericia method) was prolonged (&gt;450 ms for males and
             females) as confirmed by the central ECG assessor.

         18. Patients with a clinically significant abnormality on the screening or baseline ECG
             who in the judgment of the investigator would be at potential risk if enrolled into
             the study. (These patients could not be re-screened).

         19. Patients who needed treatments for COPD and allied conditions after the start of the
             study (visit 1)

         20. Patients who needed treatments for COPD and allied conditions (e.g. allergic rhinitis)
             unless they had been stabilized

         21. Patients taking other prohibited medications

         22. Patients unable to use a dry powder inhaler (e.g. single dose dry powder inhaler
             (SDDPI), HandiHaler® device, or pressurized Metered Dose Inhaler (MDI) (rescue
             medication).

         23. Patients unable to use an electronic patient diary.

         24. Patients who were, in the opinion of the investigator known to be unreliable or
             non-compliant.

         25. Patients who used other investigational drugs at the time of enrollment, or within 30
             days or 5 half-lives of visit 1 (day -21), whichever was longer.

         26. Patients who had live attenuated vaccination within 30 days prior to the screening
             visit or during the run-in period. Inactivated influenza vaccination, pneumococcal
             vaccination or any other inactivated vaccine was acceptable provided it was not
             administered within 48 hours prior to screening and randomization visits.

        No additional exclusions were applied by the investigator, in order to ensure that the
        study population was representative of all eligible patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209-6870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pine Bluff</city>
        <state>Arkansas</state>
        <zip>71603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Couer D'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florence</city>
        <state>Kentucky</state>
        <zip>41042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <zip>70570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ozark</city>
        <state>Missouri</state>
        <zip>65721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Massapequa</city>
        <state>New York</state>
        <zip>11758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504-8741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406-7108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1424BSF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Isidro</city>
        <state>Buenos Aires</state>
        <zip>B1609EEO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>C2000DSR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DBS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000DGF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1842DID</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos aires</city>
        <zip>B1878FNR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos aires</city>
        <zip>B2705XAE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B6500EZL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B8000XAV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1013AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1115AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos aires</city>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1122AAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1186ACB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AUA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425BEA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1440BRR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Corrientes</city>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CCG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paraná Entre Ríos</city>
        <zip>3100</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Feldbach</city>
        <zip>8330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grieskirchen</city>
        <zip>4710</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thalheim bei Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Joliette</city>
        <state>Quebec</state>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7S 2M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1G 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Romuald</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1P 1J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Armenia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cesky Krumlov</city>
        <zip>381 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cvikov</city>
        <zip>471 54</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Havlickuv Brod</city>
        <zip>580 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaromer</city>
        <zip>551 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>360 66</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kromeriz</city>
        <zip>767 55</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kutna Hora</city>
        <zip>284 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyjov</city>
        <zip>697 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liberec</city>
        <zip>460 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 09</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 4</city>
        <zip>142 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 10</city>
        <zip>108 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 9</city>
        <zip>198 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rokycany</city>
        <zip>337 22</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strakonice</city>
        <zip>38601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zatec</city>
        <zip>438 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Znojmo</city>
        <zip>669 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hellerup</city>
        <zip>DK-2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roskilde</city>
        <zip>DK-4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sønderborg</city>
        <zip>DK-6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jyvaskyla</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bayonne Cedex</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beuvry</city>
        <zip>62660</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ferolles-Attily</city>
        <zip>77150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koblenz</city>
        <state>NRW</state>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>D-12165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dueren</city>
        <zip>52349</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freudenberg</city>
        <zip>57258</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fulda</city>
        <zip>36039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gummersbach</city>
        <zip>51643</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hagen</city>
        <zip>59065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Homburg</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24148</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Langenfeld</city>
        <zip>40764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23558</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nuernberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oranienburg</city>
        <zip>16515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Radebeul</city>
        <zip>01445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reinfeld</city>
        <zip>23858</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwerte</city>
        <zip>58239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwetzingen</city>
        <zip>68723</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Solingen</city>
        <zip>42651</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stade</city>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teterow</city>
        <zip>17166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wissen</city>
        <zip>57537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens - GR</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR 11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR 12461</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR-106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR 570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cegled</city>
        <zip>2700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Makó</city>
        <zip>6900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sopron</city>
        <zip>9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szarvas</city>
        <zip>5540</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>A.p.</state>
        <zip>500 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderbabd</city>
        <state>Andhra Pradesh</state>
        <zip>500 029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur - Maharastra</city>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panjim</city>
        <zip>403002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Secunderabad</city>
        <zip>500002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trivandrum</city>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 15</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 24</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kfar-Sava</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osimo</city>
        <state>AN</state>
        <zip>60027</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Foggia</city>
        <state>FG</state>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arenzano</city>
        <state>GE</state>
        <zip>16011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Abano Terme</city>
        <state>PD</state>
        <zip>35031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riccione</city>
        <state>RN</state>
        <zip>47838</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pietra Ligure</city>
        <state>SV</state>
        <zip>17027</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montecchio Maggiore</city>
        <state>VI</state>
        <zip>36075</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64450</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78218</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Drachten</city>
        <zip>9200 DA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Enschede</city>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harderwijk</city>
        <zip>3840 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helmond</city>
        <zip>5707 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roermond</city>
        <zip>6043 CV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Voorburg</city>
        <zip>2275 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cercado de Lima</city>
        <state>Lima</state>
        <zip>01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Borja</city>
        <state>Lima</state>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Martin de Porres</city>
        <state>Lima</state>
        <zip>31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel</city>
        <state>Lima</state>
        <zip>32</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Surco</city>
        <state>Lima</state>
        <zip>33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <zip>1109</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bulacan</city>
        <zip>3020</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Pinas</city>
        <zip>1740</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-067</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mrozy</city>
        <zip>05-320</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-456</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Humacao</city>
        <zip>00791</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan Republic</state>
        <zip>420015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>S.-Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Samara</city>
        <zip>443079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.Petersburg</city>
        <zip>198044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <state>Slovak Republic</state>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bojnice</city>
        <state>Slovak Republic</state>
        <zip>972 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Humenne</city>
        <state>Slovak Republic</state>
        <zip>066 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Partizanske</city>
        <state>Slovak Republic</state>
        <zip>958 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kralovsky Chlmec</city>
        <zip>077 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Martin</city>
        <zip>03601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trnava</city>
        <zip>917 75</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newtown, Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <zip>03114</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockton</city>
        <state>Cleveland</state>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sneinton</city>
        <state>Nottingham</state>
        <zip>NG3 7DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taunton</city>
        <state>Somerset</state>
        <zip>TA1 3JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chertsey</city>
        <state>Surrey</state>
        <zip>KT16 0PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV6 4DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gillingham</city>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G21 3UW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hereford</city>
        <zip>HR1 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huntingdon</city>
        <zip>PE29 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2PR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merseyside</city>
        <zip>CH49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Telford</city>
        <zip>TF1 6TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Guatemala</country>
    <country>Norway</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2010</study_first_posted>
  <results_first_submitted>July 9, 2013</results_first_submitted>
  <results_first_submitted_qc>July 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2013</results_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QVA149</keyword>
  <keyword>NVA237</keyword>
  <keyword>COPD</keyword>
  <keyword>exacerbation</keyword>
  <keyword>combination bronchodilator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 3865 participants were screened of whom 2224 were randomized to 1 of the 3 treatment groups (QVA149, NVA237 or tiotropium) in a 1:1:1 ratio for at least 64 weeks (maximum 76 weeks) of treatment period.</recruitment_details>
      <pre_assignment_details>5 (QVA149), 2 (NVA237) and 3 (tiotropium) participants were randomized but did not receive study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>QVA149</title>
          <description>QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period. Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
        </group>
        <group group_id="P2">
          <title>NVA237</title>
          <description>NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period. Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
        </group>
        <group group_id="P3">
          <title>Open-label Tiotropium</title>
          <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="741"/>
                <participants group_id="P2" count="741"/>
                <participants group_id="P3" count="742"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="736"/>
                <participants group_id="P2" count="739"/>
                <participants group_id="P3" count="739"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set (SAF)</title>
              <participants_list>
                <participants group_id="P1" count="736"/>
                <participants group_id="P2" count="740"/>
                <participants group_id="P3" count="739"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Safety Set (mSAF)</title>
              <participants_list>
                <participants group_id="P1" count="729"/>
                <participants group_id="P2" count="740"/>
                <participants group_id="P3" count="737"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Full Analysis Set (mFAS)</title>
              <participants_list>
                <participants group_id="P1" count="729"/>
                <participants group_id="P2" count="739"/>
                <participants group_id="P3" count="737"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="570"/>
                <participants group_id="P2" count="538"/>
                <participants group_id="P3" count="559"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="183"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient's inability to use the device</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The modified safety set (mSAF set) includes all patients in the safety set except patients from a site who had major GCP issues.</population>
      <group_list>
        <group group_id="B1">
          <title>QVA149</title>
          <description>QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period. Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
        </group>
        <group group_id="B2">
          <title>NVA237</title>
          <description>NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period. Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>Open-label Tiotropium</title>
          <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="729"/>
            <count group_id="B2" value="740"/>
            <count group_id="B3" value="737"/>
            <count group_id="B4" value="2206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="8.07"/>
                    <measurement group_id="B2" value="63.1" spread="7.98"/>
                    <measurement group_id="B3" value="63.6" spread="7.79"/>
                    <measurement group_id="B4" value="63.3" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="184"/>
                    <measurement group_id="B4" value="555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="556"/>
                    <measurement group_id="B2" value="542"/>
                    <measurement group_id="B3" value="553"/>
                    <measurement group_id="B4" value="1651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period.</title>
        <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
        <time_frame>64 weeks</time_frame>
        <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site , which had major issues with Good Clinical Practice (GCP) compliance.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period.</title>
          <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
          <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site , which had major issues with Good Clinical Practice (GCP) compliance.</population>
          <units>Exacerbations per year</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="729"/>
                <count group_id="O2" value="739"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Moderate to Severe COPD Exacerbation</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="812"/>
                <count group_id="O2" value="900"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94"/>
                    <measurement group_id="O2" value="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and Open-label Tiotropium Treatment Arms During the Treatment Period.</title>
        <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
        <time_frame>76 weeks</time_frame>
        <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site, which had major issues with GCP compliance.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and Open-label Tiotropium Treatment Arms During the Treatment Period.</title>
          <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
          <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site, which had major issues with GCP compliance.</population>
          <units>Exacerbations per year</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="729"/>
                <count group_id="O2" value="737"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Moderate to Severe COPD Exacerbation</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="812"/>
                <count group_id="O2" value="898"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94"/>
                    <measurement group_id="O2" value="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Between QVA149, NVA237 and Open Label Tiotropium During the Treatment Period</title>
        <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
        <time_frame>64 weeks</time_frame>
        <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site, which had major issues with GCP compliance. Only patients with a moderate or severe COPD exacerbation were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Between QVA149, NVA237 and Open Label Tiotropium During the Treatment Period</title>
          <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
          <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site, which had major issues with GCP compliance. Only patients with a moderate or severe COPD exacerbation were included in this analysis.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296" lower_limit="267" upper_limit="358"/>
                    <measurement group_id="O2" value="287" lower_limit="255" upper_limit="325"/>
                    <measurement group_id="O3" value="331" lower_limit="280" upper_limit="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Requiring the Use of Both Systemic Glucocorticosteroids and Antibiotics</title>
        <description>Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
        <time_frame>64 weeks</time_frame>
        <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site, which had major issues with GCP compliance. The Full Analysis Set (FAS) includes all randomized patients who received at least one dose of study drug and data was available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Requiring the Use of Both Systemic Glucocorticosteroids and Antibiotics</title>
          <description>Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
          <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site, which had major issues with GCP compliance. The Full Analysis Set (FAS) includes all randomized patients who received at least one dose of study drug and data was available for analysis.</population>
          <units>exacerbations per year</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="729"/>
                <count group_id="O2" value="739"/>
                <count group_id="O3" value="737"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>exacerbations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="491"/>
                <count group_id="O3" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46"/>
                    <measurement group_id="O2" value="0.58"/>
                    <measurement group_id="O3" value="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Moderate or Severe Exacerbation That Required Treatment With Systemic Corticosteroids and Antibiotics</title>
        <description>The number of exacerbation days is defined as the sum of the duration of days recorded as an exacerbation for all exacerbations recorded per patient.</description>
        <time_frame>64 weeks</time_frame>
        <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site with GCP non-compliance. This is a sub-group analysis with mutually exclusive population in each category for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Moderate or Severe Exacerbation That Required Treatment With Systemic Corticosteroids and Antibiotics</title>
          <description>The number of exacerbation days is defined as the sum of the duration of days recorded as an exacerbation for all exacerbations recorded per patient.</description>
          <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site with GCP non-compliance. This is a sub-group analysis with mutually exclusive population in each category for analysis.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="575"/>
                <count group_id="O3" value="556"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>systemic corticosteroids [n= 97, 108, 109]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.49" spread="25.426"/>
                    <measurement group_id="O2" value="25.22" spread="42.674"/>
                    <measurement group_id="O3" value="17.57" spread="17.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>antibiotics [n= 195, 177, 177]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.08" spread="47.035"/>
                    <measurement group_id="O2" value="18.10" spread="21.790"/>
                    <measurement group_id="O3" value="25.94" spread="50.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>corticosteroids and antibiotic [n= 266, 290, 270]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.10" spread="49.999"/>
                    <measurement group_id="O2" value="26.18" spread="52.336"/>
                    <measurement group_id="O3" value="22.03" spread="42.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.) During the Treatment Period.</title>
        <description>Time to Study Withdrawal or Premature Discontinuation for Any Reason was analyzed for each treatment group using a Kaplan-Meier estimation for the modified safety set. Patients who did not discontinue early were censored at the final visit of the treatment phase.</description>
        <time_frame>64 weeks</time_frame>
        <population>Modified safety set (mSAF set) includes all patients in the safety set except patients from a site who had major GCP issues. The Safety set includes all patients who received at least one dose of study drug whether or not being randomized. Analysis population included patients with study withdrawal or premature discontinuation for any reason.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.) During the Treatment Period.</title>
          <description>Time to Study Withdrawal or Premature Discontinuation for Any Reason was analyzed for each treatment group using a Kaplan-Meier estimation for the modified safety set. Patients who did not discontinue early were censored at the final visit of the treatment phase.</description>
          <population>Modified safety set (mSAF set) includes all patients in the safety set except patients from a site who had major GCP issues. The Safety set includes all patients who received at least one dose of study drug whether or not being randomized. Analysis population included patients with study withdrawal or premature discontinuation for any reason.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Less than 50% of patients had withdrawn from the study or prematurely discontinued for any reason.</measurement>
                    <measurement group_id="O2" value="NA">Less than 50% of patients had withdrawn from the study or prematurely discontinued for any reason.</measurement>
                    <measurement group_id="O3" value="NA">Less than 50% of patients had withdrawn from the study or prematurely discontinued for any reason.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.)During the Treatment Period</title>
        <description>Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason was analyzed for each treatment group using a Kaplan-Meier estimation for the modified safety set. Patients who did not discontinue early were censored at the final visit of the treatment phase.</description>
        <time_frame>64 weeks</time_frame>
        <population>Modified safety set (mSAF set) includes all patients in the safety set except patients from a site who had major GCP issues. The Safety set includes all patients who received at least one dose of study drug whether or not being randomized</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.)During the Treatment Period</title>
          <description>Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason was analyzed for each treatment group using a Kaplan-Meier estimation for the modified safety set. Patients who did not discontinue early were censored at the final visit of the treatment phase.</description>
          <population>Modified safety set (mSAF set) includes all patients in the safety set except patients from a site who had major GCP issues. The Safety set includes all patients who received at least one dose of study drug whether or not being randomized</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="729"/>
                <count group_id="O2" value="740"/>
                <count group_id="O3" value="737"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Rates of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations for Multiple COPD Exacerbation at Different Time Points</title>
        <description>Cumulative rates were estimated using Anderson and Gill method. Chronic Obstructive Pulmonary Disease (COPD) exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if treatment for moderate severity and hospitalization were required. Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
        <time_frame>26, 52, 64, 76 weeks</time_frame>
        <population>Modified Full Analysis Set(mFAS) included all patients in the Full Analysis Set (FAS) except patients from a site, which had major issues with GCP compliance. FAS include all randomized patients who received at least one dose of study drug and data was available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks.Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Rates of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations for Multiple COPD Exacerbation at Different Time Points</title>
          <description>Cumulative rates were estimated using Anderson and Gill method. Chronic Obstructive Pulmonary Disease (COPD) exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if treatment for moderate severity and hospitalization were required. Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years</description>
          <population>Modified Full Analysis Set(mFAS) included all patients in the Full Analysis Set (FAS) except patients from a site, which had major issues with GCP compliance. FAS include all randomized patients who received at least one dose of study drug and data was available for analysis.</population>
          <units>exacerbations per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="729"/>
                <count group_id="O2" value="739"/>
                <count group_id="O3" value="737"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Moderate or Severe COPD Exacerbations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="831"/>
                <count group_id="O2" value="926"/>
                <count group_id="O3" value="897"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.51" upper_limit="0.62"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.58" upper_limit="0.71"/>
                    <measurement group_id="O3" value="0.63" lower_limit="0.56" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.91" upper_limit="1.09"/>
                    <measurement group_id="O2" value="1.13" lower_limit="1.03" upper_limit="1.25"/>
                    <measurement group_id="O3" value="1.11" lower_limit="1.00" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>64 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="1.08" upper_limit="1.30"/>
                    <measurement group_id="O2" value="1.36" lower_limit="1.24" upper_limit="1.49"/>
                    <measurement group_id="O3" value="1.31" lower_limit="1.19" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>76 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" lower_limit="1.27" upper_limit="1.53"/>
                    <measurement group_id="O2" value="1.59" lower_limit="1.45" upper_limit="1.74"/>
                    <measurement group_id="O3" value="1.55" lower_limit="1.40" upper_limit="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Forced Expiratory Volume in 1 Second (FEV-1) After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium</title>
        <description>Pulmonary function assessments were performed using centralized spirometry. The spirometer was customized and programmed according to the requirements of the study protocol in accordance with American Thoracic Society (ATS) standards.
Spirometry measurements taken were FEV1 at -45 minutes and -15 minutes pre-dose. Three acceptable maneuvers had to be performed for each time point. The FEV1 values recorded had to be the highest values measured irrespective of whether or not they occurred on the same curve.
The mixed model for analysis contained treatment as a fixed effect with average of the 45 minutes and 15 minutes pre dose FEV1 measurements at day 1 as the baseline measurement, FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at -14 Day) as covariates.</description>
        <time_frame>4, 12, 26, 38, 52 and 64 weeks</time_frame>
        <population>Modified Full Analysis Set(mFAS) included all patients in the Full Analysis Set (FAS) except patients from a site, which had major issues with GCP compliance. FAS include all randomized patients who received at least one dose of study drug and data was available for analysis. Each category has patients with assessable data at that particular time.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Forced Expiratory Volume in 1 Second (FEV-1) After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium</title>
          <description>Pulmonary function assessments were performed using centralized spirometry. The spirometer was customized and programmed according to the requirements of the study protocol in accordance with American Thoracic Society (ATS) standards.
Spirometry measurements taken were FEV1 at -45 minutes and -15 minutes pre-dose. Three acceptable maneuvers had to be performed for each time point. The FEV1 values recorded had to be the highest values measured irrespective of whether or not they occurred on the same curve.
The mixed model for analysis contained treatment as a fixed effect with average of the 45 minutes and 15 minutes pre dose FEV1 measurements at day 1 as the baseline measurement, FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at -14 Day) as covariates.</description>
          <population>Modified Full Analysis Set(mFAS) included all patients in the Full Analysis Set (FAS) except patients from a site, which had major issues with GCP compliance. FAS include all randomized patients who received at least one dose of study drug and data was available for analysis. Each category has patients with assessable data at that particular time.</population>
          <units>L (liters)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="729"/>
                <count group_id="O2" value="739"/>
                <count group_id="O3" value="737"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose FEV1 Week 4 (n= 656,654,630)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.009"/>
                    <measurement group_id="O2" value="0.99" spread="0.009"/>
                    <measurement group_id="O3" value="1.00" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>predose FEV1 Week 12 (n= 666,663,653)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.010"/>
                    <measurement group_id="O2" value="1.01" spread="0.009"/>
                    <measurement group_id="O3" value="1.01" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>predose FEV1 Week 26 (n= 604,577,599)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.010"/>
                    <measurement group_id="O2" value="0.99" spread="0.010"/>
                    <measurement group_id="O3" value="1.00" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>predose FEV1 Week 38 (n= 593,549,583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.011"/>
                    <measurement group_id="O2" value="1.00" spread="0.011"/>
                    <measurement group_id="O3" value="1.00" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>predose FEV1 Week 52 (n= 557,538,548)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.011"/>
                    <measurement group_id="O2" value="0.98" spread="0.011"/>
                    <measurement group_id="O3" value="0.99" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>predose FEV1 Week 64 (n= 549,504,530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.011"/>
                    <measurement group_id="O2" value="0.98" spread="0.011"/>
                    <measurement group_id="O3" value="0.99" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Forced Vital Capacity (FVC)After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium</title>
        <description>Pulmonary function assessments were performed using centralized spirometry. The spirometer was customized and programmed according to the requirements of the study protocol in accordance with American Thoracic Society (ATS) standards.
Pre-dose Forced Vital Capacity (FVC) is defined as the average of the -15 minutes and the -45 minutes FVC values. Baseline is defined as the average of the -45 minutes and -15 minutes FVC values taken on day 1 prior to first dose. FVC data taken within 6h of rescue medication or within 7 days of systemic corticosteroid is excluded from this analysis</description>
        <time_frame>4, 12, 26, 38, 52 and 64 weeks</time_frame>
        <population>Modified Full Analysis Set(mFAS) included all patients in the Full Analysis Set (FAS) except patients from a site, which had major issues with GCP compliance. FAS include all randomized patients who received at least one dose of study drug and data was available for analysis. Each category has patients with assessable data at that particular time.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Forced Vital Capacity (FVC)After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium</title>
          <description>Pulmonary function assessments were performed using centralized spirometry. The spirometer was customized and programmed according to the requirements of the study protocol in accordance with American Thoracic Society (ATS) standards.
Pre-dose Forced Vital Capacity (FVC) is defined as the average of the -15 minutes and the -45 minutes FVC values. Baseline is defined as the average of the -45 minutes and -15 minutes FVC values taken on day 1 prior to first dose. FVC data taken within 6h of rescue medication or within 7 days of systemic corticosteroid is excluded from this analysis</description>
          <population>Modified Full Analysis Set(mFAS) included all patients in the Full Analysis Set (FAS) except patients from a site, which had major issues with GCP compliance. FAS include all randomized patients who received at least one dose of study drug and data was available for analysis. Each category has patients with assessable data at that particular time.</population>
          <units>L (liters)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="729"/>
                <count group_id="O2" value="739"/>
                <count group_id="O3" value="737"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose FVC Week 4 (n= 656,654,630)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" spread="0.020"/>
                    <measurement group_id="O2" value="2.59" spread="0.019"/>
                    <measurement group_id="O3" value="2.60" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>predose FVC Week 12 (n= 623,621,619)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="0.021"/>
                    <measurement group_id="O2" value="2.63" spread="0.021"/>
                    <measurement group_id="O3" value="2.65" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>predose FVC Week 26 (n= 604,577,599)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="0.023"/>
                    <measurement group_id="O2" value="2.60" spread="0.022"/>
                    <measurement group_id="O3" value="2.61" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>predose FVC Week 38 (n= 592,548,580)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="0.025"/>
                    <measurement group_id="O2" value="2.65" spread="0.025"/>
                    <measurement group_id="O3" value="2.63" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>predose FVC Week 52 (n= 557,538,547)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="0.025"/>
                    <measurement group_id="O2" value="2.58" spread="0.025"/>
                    <measurement group_id="O3" value="2.58" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>predose FVC Week 64 (n= 549,502,526)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="0.025"/>
                    <measurement group_id="O2" value="2.57" spread="0.025"/>
                    <measurement group_id="O3" value="2.59" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Daily Use (Number of Puffs) of Rescue Therapy Between QVA149, NVA237 and Open Label Tiotropium From Baseling Over the 64 Week Treatment Period</title>
        <description>The severe or less FEV1 % predicted (post bronchodilator)&gt;=30%; very severe=&gt; FEV1 % predicted(the post bronchodilator)&lt;30%.Number of puffs of rescue medication taken in the previous 12 hours was recorded in patient diary in the morning and in the evening for 26 weeks.The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient.Rescue medication data recorded during the 14 day run-in was used to calculate the baseline.A negative change from baseline indicates improvement. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates.</description>
        <time_frame>Baseline (14 day run-in), 64 weeks</time_frame>
        <population>Modified Full Analysis Set mFAS included all patients in the Full analysis set except patients from a site,which had major issues with GCP compliance. The Full Analysis Set includes all randomized patients who received at least one dose of study drug and data was available for analysis. Patients with evaluable data were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Daily Use (Number of Puffs) of Rescue Therapy Between QVA149, NVA237 and Open Label Tiotropium From Baseling Over the 64 Week Treatment Period</title>
          <description>The severe or less FEV1 % predicted (post bronchodilator)&gt;=30%; very severe=&gt; FEV1 % predicted(the post bronchodilator)&lt;30%.Number of puffs of rescue medication taken in the previous 12 hours was recorded in patient diary in the morning and in the evening for 26 weeks.The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient.Rescue medication data recorded during the 14 day run-in was used to calculate the baseline.A negative change from baseline indicates improvement. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates.</description>
          <population>Modified Full Analysis Set mFAS included all patients in the Full analysis set except patients from a site,which had major issues with GCP compliance. The Full Analysis Set includes all randomized patients who received at least one dose of study drug and data was available for analysis. Patients with evaluable data were included in this analysis</population>
          <units># puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="708"/>
                <count group_id="O2" value="724"/>
                <count group_id="O3" value="709"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Daily # puffs Severe or Less(n=565,575,561)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="0.137"/>
                    <measurement group_id="O2" value="-1.5" spread="0.135"/>
                    <measurement group_id="O3" value="-1.6" spread="0.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Daily # puffs Very Severe (n=143,149,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.234"/>
                    <measurement group_id="O2" value="-1.1" spread="0.228"/>
                    <measurement group_id="O3" value="-1.0" spread="0.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Percentage of Days Without Rescue Therapy Use Between QVA149,NVA237 and Open Label Tiotropium Over the 64 Week Treatment Period</title>
        <description>A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. The percentage of days is calculated by the number of days with no rescue medicine use/total number of days with evaluable data X 100. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.</description>
        <time_frame>Baseline (14 day run-in), 64 weeks</time_frame>
        <population>Modified Full Analysis Set(mFAS)included all patients in the Full analysis set except patients from a site,which had major issues with GCP compliance. The Full Analysis Set includes all randomized patients who received at least one dose of study drug and data was available for analysis. Patients with evaluable data were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Percentage of Days Without Rescue Therapy Use Between QVA149,NVA237 and Open Label Tiotropium Over the 64 Week Treatment Period</title>
          <description>A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. The percentage of days is calculated by the number of days with no rescue medicine use/total number of days with evaluable data X 100. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.</description>
          <population>Modified Full Analysis Set(mFAS)included all patients in the Full analysis set except patients from a site,which had major issues with GCP compliance. The Full Analysis Set includes all randomized patients who received at least one dose of study drug and data was available for analysis. Patients with evaluable data were included in this analysis</population>
          <units>percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="720"/>
                <count group_id="O3" value="703"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.36" spread="1.445"/>
                    <measurement group_id="O2" value="21.65" spread="1.410"/>
                    <measurement group_id="O3" value="23.86" spread="1.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St. George's Respiratory Questionnaire (SGRQ) Scores Between QVA149, NVA237 and Open Label Tiotropium Over 12, 26, 38, 52 and 64 Weeks of Treatment</title>
        <description>St. George's Respiratory Questionnaire (SGRQ) is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life. Mixed model used baseline SGRQ, baseline inhaled corticosteroid (ICS) use, Forced Expiratory Volume in 1 Second (FEV1) prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates. SGRQ total score is the sum of the scores from the three components; symptoms, activity and impacts.</description>
        <time_frame>12, 26, 38, 52 and 64 weeks</time_frame>
        <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site, which had major issues with GCP compliance. The Full Analysis Set (FAS) includes all randomized patients who received at least one dose of study drug and data was available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>QVA149</title>
            <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>NVA237</title>
            <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI)for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Open-label Tiotropium</title>
            <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>St. George's Respiratory Questionnaire (SGRQ) Scores Between QVA149, NVA237 and Open Label Tiotropium Over 12, 26, 38, 52 and 64 Weeks of Treatment</title>
          <description>St. George's Respiratory Questionnaire (SGRQ) is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life. Mixed model used baseline SGRQ, baseline inhaled corticosteroid (ICS) use, Forced Expiratory Volume in 1 Second (FEV1) prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates. SGRQ total score is the sum of the scores from the three components; symptoms, activity and impacts.</description>
          <population>Modified Full Analysis Set (mFAS) included all patients in the Full analysis set except patients from a site, which had major issues with GCP compliance. The Full Analysis Set (FAS) includes all randomized patients who received at least one dose of study drug and data was available for analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="729"/>
                <count group_id="O2" value="739"/>
                <count group_id="O3" value="737"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n= 694,694,676)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.69" spread="0.612"/>
                    <measurement group_id="O2" value="47.13" spread="0.603"/>
                    <measurement group_id="O3" value="47.62" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n= 684,677,658)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.06" spread="0.655"/>
                    <measurement group_id="O2" value="45.93" spread="0.647"/>
                    <measurement group_id="O3" value="45.77" spread="0.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 38 (n= 648,626,635)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.72" spread="0.667"/>
                    <measurement group_id="O2" value="45.53" spread="0.663"/>
                    <measurement group_id="O3" value="45.86" spread="0.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n= 625,593,613)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.38" spread="0.722"/>
                    <measurement group_id="O2" value="45.96" spread="0.723"/>
                    <measurement group_id="O3" value="46.21" spread="0.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64 (n= 600,564,579)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.39" spread="0.778"/>
                    <measurement group_id="O2" value="45.46" spread="0.780"/>
                    <measurement group_id="O3" value="46.08" spread="0.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Modified safety set (mSAF set) includes all patients in the safety set except patients from a site who had major GCP issues. The Safety set includes all patients who received at least one dose of study drug whether or not being randomized. Analysis population included patients with study withdrawal or premature discontinuation for any reason.</desc>
      <group_list>
        <group group_id="E1">
          <title>QVA149</title>
          <description>QVA149 : QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
        </group>
        <group group_id="E2">
          <title>NVA237</title>
          <description>NVA237 : NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
        </group>
        <group group_id="E3">
          <title>Open-label Tiotropium</title>
          <description>Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device. for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="165" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cor pulmonale chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital laryngeal stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Intestinal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Abscess rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Rabies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Osteochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the caecum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Gliosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Mediastinum neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Bladder dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pulmonary air leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Vocal cord inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Pollution</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Phlebitis deep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="656" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="671" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="666" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="618" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="639" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="629" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="737"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="729"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="740"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="737"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

